Belite Bio, Inc (BLTE) company profile

Belite Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for debilitating retinal conditions with significant unmet needs. Its primary candidate is tinlarebant, an oral once-daily tablet designed to combat Geographic Atrophy associated with dry age-related macular degeneration and Stargardt disease type 1, which lead to progressive vision loss. The company's development pipeline also encompasses LBS-009, an oral small molecule aimed at treating metabolic disorders including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Tinlarebant primarily targets adolescent and adult patients suffering from degenerative eye disorders.

The company operates internationally, maintaining corporate entities and clinical trial activities across several territories including the United States, Australia, China, Hong Kong, Taiwan, Switzerland, and Japan. Its global clinical programs enroll patients worldwide across multi-center studies. Belite Bio maintains its principal executive offices in San Diego, California, and retains a registered office in Grand Cayman, Cayman Islands.

Summary of the business section of Belite Bio's latest annual report, written by StockData.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business which has fewer than 500 employees; in assessing whether an application qualifies as a ‘first application’ and calculating the number of employees, affiliates of the small business making the NDA submission are considered.”